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Copyright © 2008 JCBN Summary Cephalotaxus sinensis (C. sinensis) large size, evergreen tree common in China and
utilized for numerous effective pharmacological applications in Chinese traditional medicine.
The hepato-renal effects of C. sinensis were evaluated in vivo using Streptozotocin (STZ)-
induced diabetic rats as an tentative model. Animals were orally treated with 80% EtOH
extract (aq.EE), H2O  extract (WtE) and ethylacetate (EaF)/butanol fractions (BtF) of C.
sinensis (200 mg/kg, b.w.) for 28 days whereas control received vehicle merely. The degree of
fortification was measured by using biochemical parameters like serum transaminases (ALT
and AST), alkaline phosphatase (ALP), creatinine, urea and urine sugar. Meanwhile, the
histopathological studies were conducted out to support the above parameters. Administration
of C. sinensis aq.EE/BtF (p<0.05) and EaF (p<0.01) patently prevented STZ-induced elevation
levels of serum ALT, AST, ALP, creatinine, urea, urine sugar and increase body weight respec-
tively, which were comparable with the standard drug tolbutamide, while WtE did not show
any significant effect (p>0.05). Phytochemical studies revealed the presence of saponins,
terpenes, sterols and flavonoids in C. sinensis which could be responsible for the possible
hepato-renal protective action. The results sustain the fact that the extract/fractions of C.
sinensis have an immense potential to be developed further into a phytomedicine.
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Introduction
The use of herbal medicine is widespread, which are used
by the people for the treatment of disparate diseases even at
this modern era. There are diverse medicinal plants in the
world, which are the impending sources of the drugs. These
drugs are invariably single plant extracts or fractions or
mixtures of extracts/fractions from different plants, which
have been carefully standardized for their safety and
efficacy [1]. Now a days, scientists and researchers are very
much tiring on research of natural plant products all over the
world and a large number of substantiation have shown the
immense potential of medicinal plants used traditionally [2].
Liver diseases are a leading health problem after cardio-
vascular disease (CVD) cancer and AIDS. During chronic
liver injury, hepatic progenitor cells (HPCs; oval cells)
appear in periportal liver regions, then undergo proliferation,
migration and differentiation to replenish hepatocytes and
biliary cells. This occurs in numerous rodent models and
human diseases such as Hepatitis B, C, hemochromatosis
and alcoholic liver disease [3]. Herbal drugs play a major
role in the treatment of hepatic disorders. A number of
medicinal plants and their formulations are used to cureM.K. Saeed et al.
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hepatic disorders in traditional systems of medicine [4]. In
addition to these known plants, there are unexplored group
of plants used by tribal and folk medical practitioners which
are a promising source of effective hepatoprotective agents
[5].
The genus Cephalotaxus, evergreen trees of southern
Asia, composed of 10 species, eight of which are distributed
in China. Cephalotaxus (C.) sinensis (Rehd et Wile) Li, large
sized, evergreen tree common in China, traditionally it is
used against dyspepsia, ascariasis, inflammation and cough
[6]. Investigations of the chemical constituents of extracts
of Cephalotaxus sps. resulted in the isolation of lactones,
flavonoids and a number of alkaloids [7–9]. Recently,
osteoblast differentiation stimulating activity of biflavonoids
from Cephalotaxus koreana Nakai (Cephalotaxaceae) have
been reported [10]. In the screening of anti-diabetic natural
substances in our labortary, it was found that the ethanol
extract of the leaves of C. sinensis possess hypoglycemic
activity, our recent studies also revealed that the pharmaco-
logical activity of this plant may be due to flavonoids.
The intention of the present study was to scrutinize the
influence of oral administration of C. sinensis extracts and
fractions on the levels of biochemical parameters and to as-
certain the scientific basis for the use of this plant in the man-
agement of liver and kidney injuries using streptozotocin-
induced diabetic rats.
Materials and Methods
Instruments and chemicals
An Elite P230 series HPLC–DAD system consisting of
binary pump and DAD detector (DAD230, Dalian Elite,
PR China) was used for acquiring chromatogram, UV-VIS
2550 spectrophotometer (Shimadzu, Japan), Biofuge 22 R
(Heraeus, Germany), light microscope and rotary evaporator
(PR China) were used for study. Streptozotocin (STZ),
hematoxylin, eosin and assay kits for serum alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
alkaline phosphates (ALP), cretinine and urea were
purchased from Sigma Chemical Co., St. Louis, MO. All the
other chemicals and solvents were of analytical grade.
Plant material
Leaves of Cephalotaxus sinensis were collected from
Anhui province, PR China and the plant were authenticated
by Professor Dr. Yulin Deng (Dean, School of Life Science
and Technology, Beijing Institute of Technology, Beijing, PR
China) and Associate Researcher Bing Wen (Xishuanbanna
Tropical Botanical Garden, Chinese Academy of Sciences, PR
China). Voucher specimen (No. S20041101) were deposited
at the School Herbarium for future references.
Preliminary screening
The ethanolic extract was subjected to preliminary
screening, for various active phytochemical constituents
such as alkaloids, carbohydrates, steroids, protein, tannins,
flavonoids, mucilage, glycosides, saponins and terpenes [11].
HPLC Analysis
HPLC analysis were performed on Elite P230 series
HPLC–DAD system consisting of binary pump and DAD
detector (DAD-230, Dalian Elite, PR China) A Kromasil C18
analytical column (250 mm × 4.6 mm i.d., 5 µm, AKZO
Nobel Inc., Sweden) coupled with a C18 guard column
(10 × 8 mm i.d., 5 µm, Tianhe Inc., PR China) was used at
room temperature. The optimum conditions were as: mobile
phase H2O-ACN (1:1), linear gradient mode, 5–40 min,
flow-rate was 0.7 ml/min, wavelength 254 nm. For HPLC
analysis ethanol extract was dissolve in methanol and
filtered through a 0.22 µm membrane filter and injected
(10 µl) in triplicate [12].
Acute toxicity studies
Healthy adult Wistar albino rats of either sex, starved
overnight were divided into four groups (n = 6) and were
orally fed with the aqueous ethanolic extract of C. sinensis in
escalating dose levels of 100, 500, 1000 and 3000 mg/kg
body weight [13]. The rats were pragmatic continuously for
2 h for behavioral, neurological and autonomic profiles and
after a period of 24 and 72 h for any lethality or death [14].
Extraction and fractionation
About 500 g of the dry leaf powder was extracted with
80% ethanol at 80°C for 3 h. The above procedures were
repeated three time. The combined ethanolic extract were
concentrated in a rotary evaporator at reduced pressure to
obtain about 172.5 g (34.5%, w/w) of extract. The ethanol
extract was then suspended in distilled water and partitioned
sequentially with petroleum ether, chloroform, ethyl acetate
and n-butanol.
Animals
Male Wistar rats (270–315 g) were selected for the study
and maintained at a controlled temperature of 25–28°C with
a 12 h light/dark cycle and fed a standard diet and water ad
libitum. Animal studies were conducted according to the
Institute of Animal Ethics Committee regulations approved
by the Committee for the Purpose of Control and Supervi-
sion of Experiments on Animals (CPCSEA).
Induction of diabetes
Diabetes was induced in the male rats by a single
intraperitoneal injection of STZ (65 mg/kg body weight)
dissolved in 10 mM sodium citrate buffer (pH 4.0), while
the control group was injected with the buffer only. StableAttenuation of Biochemical Parameters in Streptozotocin-induced Diabetic Rats
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hyperglycemia was confirmed by estimating the glucose
level in urine of rats.
Experimental procedure
The rats were alienated into seven groups (six in each
group). Group I, normal rats + vehicle (solution of normal
saline and 3.0% tween 80); Group II, untreated diabetic +
vehicle; Group III, diabetic + tolbutamide (25 mg/kg body
weight, p.o.); Group IV, diabetic + 80% aqueous ethanolic
extract (aq.EE); Group V, diabetic + water extract (WtE);
Group VI, diabetic + ethylacetate fraction (EaF) and Group
VII, diabetic + Butanol fraction (BtF) (200 mg/kg body
weight) daily by gastric intubations for a period of 28 days.
All the extracts and fractions were dissolves in vehicle
(solution of normal saline and 3.0% tween 80). All groups
were sacrificed on the 28th day in fasting condition by
cervical dislocation. Body weights of all the animals were
recorded weakly, prior to the treatments and sacrifice.
Biological assays
Rats of all groups were anaesthetized by ether, the blood
samples of each animal were taken by puncturing retro-orbital
plexus and allowed to clot for 60 min at room temperature.
Serum was separated by centrifugation at 3000 rpm at 25°C
for 15 min and analyzed for assorted biochemical parameters.
The serum ALT [15],  AST [16], ALP [17] activities,
cretinine [18] and urea [19] were measured using the respec-
tive spectrophotometric diagnostic kit obtained from
Biosino Biotechnology Company Ltd. (Beijing, PR China).
The urine glucose level of rats was measured by benedict’s
qualitative test.
Histological preparation
The liver was fixed in a neutral buffered formalin solution
(10%) and dehydrated in a graded series (50%, 70%, 80%,
90%, 95%, and 100%) of ethanol. The tissue was embedded
in Paraplast, sectioned into approximately 4 µm thickness
and stained with hematoxylin and eosin (H&E). The tissues
were observed using a light microscope.
Statistical analysis
Results were articulated as mean ± SD and all statistical
comparisons were made by means of one-way ANOVA test
followed by Tukey post hoc analysis and p values less than
or equal to 0.05 were considered significant.
Results
Preliminary chemical tests
Our phytochemical studies indicated that ethanolic extract
of leaves of C. sinensis contains alkaloids, flavonoids,
glycosides, saponins terpenes and steroids, while mucilage
and proteins were absent.
HPLC analysis
The optimized chromatogram of ethanol extract of C.
sinensis was given in Fig. 1. Optimization of parameters in
HPLC was done through investigating the influence of the
mobile phase and detection wavelength, because these two
parameters play a key role on resolution and sensitivity. In
this work, a water and acetonitrile (1:1) was chosen as the
mobile phase. HPLC chromatogram of ethanol extract of
C. sinensis showed 18 common peaks.
Acute toxicity studies
In performing preliminary tests for pharmacological
activity in rats, aqueous ethanolic extract did not produce
any significant changes in the auto-nomic, behavioral or
neurological responses up to doses of 3000 mg/kg body wt.
Acute toxicity studies revealed the non-toxic nature of the
aqueous ethanolic extract of C. sinensis.
Effect on body weight and urine sugar
The final body weight of untreated control group was
significantly increased than at the beginning of the experi-
ment, on the contrary a significant increase urine glucose
level and decrease body weight was observed in diabetic
treated group (p<0.001). On the other hand, the administra-
tion of EaF (p<0.01), BtF, 80% ethanol extract (p<0.05) of
C. sinensis increase body weight and decrease urine glucose
levels respectively, while water extract did not show any
significant effect (p>0.05). The changes in body weights and
urine glucose levels in all groups of animals were given in
Fig. 2 and Table 1.
Effect on biochemical parameters
In order to examine the effect of C. sinensis supplementa-
tion on the regulation of biochemical parameters of the
diabetic rats, serum ALT, AST and ALP levels were deter-
mined to evaluate the hepatic functions, while creatinine and
Fig. 1. HPLC chromatograph of Cephalotaxus sinensisM.K. Saeed et al.
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urea concentrations were studied to assess the renal func-
tions. STZ induced significant elevations in ALT, AST, ALP,
creatinine and urea serum levels (p<0.001) when compared
to control values. EaF (200 mg/kg, b.w, p.o.) of C. sinensis
supplementation significantly reduced the ALT, AST, ALP,
creatinine and urea serum levels (p<0.01) and the activities
became similar with the standard drug (tolbutamide, 25
mg/kg, b.w, p.o.) administrated group. On the other hand,
the administration of BtF and 80% ethanol extract (200
mg/kg, b.w, p.o.) of C. sinensis also significantly reduced the
levels of these parameters (p<0.05), while the effect of water
extract was insignificant (p>0.05) as depicted in Table 2.
Histological appearance of the liver
In order to obtain more information on liver damage as a
result of the induction of type 1 diabetes and the possible
recovery effect of C. sinensis on the hepatic injury, the
histological studies of liver was carried out which were
sacrificed after 28 days of the experiment (Table 3). Histology
of the liver sections of normal control animals showed
normal liver architecture with well brought out central
vein, well-preserved cytoplasm and prominent nucleus and
nucleolus (Fig. 3A). On the contrary, the STZ-induced
diabetic rat, displayed feathery degeneration, micro and
macro cellular fatty changes and inflammatory cells around
Fig. 2. Effect of treatment with 80% ethanol extract (aq.EE), water extract (WtE), ethylacetate fraction (EaF), butanol fraction (BtF) of
C. sinensis and standard drug (SD) tolbutamide on changes in body weights in normal and diabetic (D) rats. (*p<0.05,
**p<0.01, #p<0.001).
Table 1. Effect of 4-week treatment with various extracts and fractions of C. sinensis on body weight (g) and urine sugar in
normal and STZ induced diabetic rats.
All values are expressed as mean ± S.E.M. (n = 6) except for urine sugar. Diabetic control was compared with untreated
control and extracts/fractions were compared with the diabetic control. *p<0.05, **p<0.01,  #p<0.001. Urine sugar (+)
indicates is equal or less than 0.25%; (++) indicates more than 2% and (+++) indicates more than 5% sugar. EaF: ethylacetate
fraction of C. sinensis 200 mg kg−1 day−1 p.o. for 28 days. BtF: butanol fraction of C. sinensis 200 mg kg−1 day−1 p.o. for 28
days. Tolbutamide: 25 mg kg−1 day−1 p.o. for 28 days.
Group
Duration of treatment and body weight Urine sugar
Day 1 Day 14 Day 28
Untreated (+) control 290.12 ± 3.5 316.90 ± 3.7 332.82 ± 4.3 —
Diabetic (–) control 280.33 ± 3.2# 265.70 ± 2.9# 262.73 ± 3.1# +++#
Diabetic + tolbutamide 304.65 ± 4.1** 317.20 ± 4.2*** 324.95 ± 4.3** +**
Diabetic + 80% EtOH extract 274.35 ± 2.3* 280.62 ± 2.4* 283.55 ± 2.4* +*
Diabetic + H2O extract 266.20 ± 2.2 269.50 ± 2.3 272.00 ± 2.2 ++
Diabetic + EaF 310.85 ± 4.2** 319.75 ± 4.4** 326.95 ± 4.3** +**
Diabetic + BtF 283.41 ± 3.1* 293.62 ± 3.2* 296.01 ± 3.3* +*Attenuation of Biochemical Parameters in Streptozotocin-induced Diabetic Rats
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portal tract (Fig. 3B). The diabetic + tolbutamide (standard
drug, 25 mg/kg b.w. p.o.)) treated animals showed an
excellent protection from STZ-induced changes in the liver
(Fig. 3C). The diabetic + 80 % ethanolic extract and butanol
fraction treated animals also showed a good protection
from STZ-induced changes in the liver (Fig. 3D, 3F). The
histopathological examination of ethylacetate fraction of C.
sinensis (200 mg/kg b.w. p.o.) group clearly indicated
that the hepatic cells, central vein, and portal triad were
comparable to standard drug administrated group (Fig. 3E).
Discussion
Traditional Chinese medicines have been used by over
one-fifth of the world population since ancient times and is a
potential source of pharmaceutical remedies [20–22]. Now a
major challenge to curing liver and kidney injuries are to
find novel chemical entities with less toxicity and greater
effectiveness than those used in current chemotherapy.
In this study, we attempted to use scientific methods to
elucidate the hepato-renal effects of C. sinensis to justify its
use in folk medicine. In order to obtain a large amount of
detectable and stronger peaks in the HPLC chromatogram,
the spectra of all peaks in the chromatogram of sample
was investigated with photodiode array detection. The
programmed wavelength gave the best absorbance for target
compounds within the chromatographic windows: 0–40 min,
254 nm. The optimization strategy consisted on obtaining as
many peaks as possible in only one run in accordance with
well-known optimization strategies [23]. There were total
eighteen common peaks obtained in the chromatograph of
C. sinensis, most of them were flavonoids by HPLC–DAD
analysis as given in Fig. 1.
In respect to LD50 values and maximum non-fatal doses
studies revealed the non-toxic nature of the aqueous ethanol
extract of this plant. There was no lethality or any toxic
reactions found at any of the doses selected until the end of
the study period. According to a toxicity classification [24],
the ethanol extract of C. sinensis was non toxic. Toxicity
studies showed that the hematological and biochemical
parameters were within normal range. The body weight
was significantly decreased in STZ-diabetic rats [25], the
administration of C. sinensis extract and fractions increases
the body weight in STZ-diabetic rats as described in Fig. 2.
The ability of C. sinensis to protect massive body weight
loss seems to be due to its ability to reduce hepato-renal
dysfunction. It might enhance glucose utilization and im-
prove diabetes associated disorders because it significantly
decreased the urine glucose level as depicted in Table 1.
Table 2.E ffect of various extracts and fractions of C. sinensis on serum profile in normal and STZ induced diabetic rats
after 28 days of treatment.
All values are expressed as mean ± S.E.M. (n = 6) except for urine sugar. Diabetic control was compared with untreated
control and extracts/fractions were compared with the diabetic control. *p<0.05, **p<0.01, #p<0.001. D: diabetic. 80% EE:
80% ethanol extract. WtE: water extract. EaF: ethylacetate fraction of C. sinensis 200 mg kg−1 day−1 p.o. for 28 days. BtF:
butanol fraction of C. sinensis 200 mg kg−1 day−1 p.o. for 28 days. Tolbutamide: 25 mg kg−1 day−1 p.o. for 28 days.
Biochemical parameters
Group ALT (U/L) AST(U/L) ALP(U/L) Creatinine (mg/dl) Urea (mg/dl)
Untreated control 37.60 ± 0.7 139.15 ± 3.6 120.30 ± 2.4 0.85 ± 0.1 52.50 ± 2.1
Diabetic control 68.30 ± 1.5# 172.30 ± 4.2# 158.35 ± 2.6# 1.40 ± 0.3# 84.85 ± 2.4#
D + tolbutamide 44.52 ± 1.2** 145.75 ± 3.6** 131.25 ± 2.2** 0.92 ± 0.1** 59.42 ± 1.9**
D + 80% EE 57.34 ± 1.3* 155.65 ± 3.3* 141.25 ± 2.1* 1.16  ± 0.2* 69.32 ± 2.2*
D + WtE 64.87 ± 1.4 163.76 ± 3.8 152.72 ± 2.5 1.30 ± 0.3 79.84 ± 2.3
D + EaF 48.15 ± 1.1** 142.89 ± 3.1** 134.50 ± 1.9** 0.98 ± 0.1** 63.15 ± 2.1**
D + BtF 51.84 ± 1.2* 146.37 ± 3.4* 137.83 ± 2.1* 1.07 ± 0.2* 65.70 ± 2.2*
Table 3.E ffect of C. sinensis on histopathological damages in
STZ-induced liver damage in rats.
All values are expressed as mean ± S.E.M. (n = 6). —: absent; +:
mild; ++: moderate; +++: severe. D: diabetic. 80% EE: 80%
ethanol extract. WtE: water extract. EaF: ethylacetate fraction of
C. sinensis 200 mg kg−1 day−1 p.o. for 28 days. BtF: butanol fraction
of C. sinensis 200 mg kg−1 day−1 p.o. for 28 days. Tolbutamide:
25 mg kg−1 day−1 p.o. for 28 days.
Microscopic observation
Groups Fatty changes
Infiltration of 
lymphocyte
Deformation in 
hepatocyte
Untreated control ———
Diabetic control +++ +++ +++
D + tolbutamide + + +
D + 80% EE ++ ++ ++
D + WtE +++ +++ +++
D+E a F + + +
D + B t F + ++ ++ +M.K. Saeed et al.
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One of the most sensitive and dramatic indicators of
kidney injury is to increase the creatinine and urea level in
serum and in hepatocyte injury is the release of intracellular
enzymes, such as transaminases and serum alkaline phos-
phatase in the circulation after STZ administration. The
enzyme ALP is located in the cytoplasm and will be released
into circulation after cellular damage [26]. In addition, the
soluble enzymes ALT/AST are released when injury
involves organelles such as mitochondria [27]. As a result,
the establishment of liver injury in this study caused both
plasma membrane and organelle membrane damage. Rajesh
and Latha [28] also reported that the elevated activities of
these enzymes were indicative of cellular leakage and loss of
the functional integrity of the cell membranes. In the present
study, STZ caused histopathological damages to the rat liver
(Fig. 3B) and increased the serum level of hepatic enzymes
AST, ALT and ALP (Table 2). The diabetic hyperglycemia
induces elevation of the serum levels of urea and creatinine
which were considered as significant markers of renal
dysfunction [29]. The results in Table 2 showed significant
(p<0.001) increase in the level of serum urea and creatinine
in the diabetic groups. After the treatment of STZ-diabetic
rats with the C. sinensis extract and fractions the level of
urea was significantly decreased with the mean value of
diabetic group. Similarly, the elevation of creatinine level
caused by diabetes was declined after the administration
of the C. sinensis extract and fractions (p<0.05; p<0.01),
compared with the diabetic group. The stabilization of
these renal parameters and enzyme levels by the ethylacetate
fraction, butanol fraction and aq. ethanolic extract of
C. sinensis was a clear indication of the improvement of
the functional status of the liver and kidney. These findings
can be further corroborated with histopathological studies
(Table 3). The histopathological examination clearly
demonstrated that the hepatic cells, central vein and portal
triad were almost normal in EaF of C. sinensis group as
compared to the group treated with STZ alone (Fig. 3E).
In phytochemical screening of this plant, alkaloids,
Fig. 3. Photomicrographs of rats liver stained by haematoxylin and eosin of untreated control (A), STZ-induced diabetic (B),
diabetic + tolbutamide (C), diabetic + aq. ethanolic extract (D), diabetic + ethylacetate fraction (E), diabetic + butanol fraction
of C. sinensis. Microscope magnification (×400).Attenuation of Biochemical Parameters in Streptozotocin-induced Diabetic Rats
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saponins, terpenes, sterols, and flavonoids were identified.
The extract might be containing β-sitosterol, a component
reported as a hepatoprotective agent [30] and flavonoids as
antioxidant compounds [31]. The identified class of compo-
nents in single or in combination with other components
present in the extract/fractions show its hepato-renal protec-
tive effects against STZ by different mechanisms, such as:
enhancing the enzymes responsible for antioxidant activity;
scavenging free radicals responsible for cell damage; or
induction of regeneration of the liver cells. Furthermore,
CYP2E1-dependent oxidative stress following the induction
of CYP2E1 by STZ is believed to be one of the main causes
of hepatotoxicity [32]. Therefore, it was possible that C.
sinensis may reduce the level of oxidative stress-related
cellular toxicity produced by CYP2E1 induction in type 1
diabetes. The increase in ROS production, lipid peroxidation
and the decrease in antioxidant defense are common in said
disease [33,  34]. These results showed that, among the
tissues (liver and kidney) tested; C. sinensis administration
to a diabetic rat may cause the protection against CYP2E1-
related oxidative stress in the liver. It was also shown that the
histopathological change in the liver tissue by STZ-diabetes
was recovered by the C. sinensis treatment. This suggested
the possibility of a curative effect of the antioxidant on
diabetic liver damage.
A few literature is available on genera Cephalotaxus,
Takano et al. isolated drupangtonine, a novel antileukemic
alkaloid from Cephalotaxus harringtonia var. drupacea
[35], Delfel & Rothfus isolated antitumor alkaloids in callus
cultures of Cephalotaxus harringtonia [36] and Morita et al.
also reported cytotoxic alkaloids from C. harringtonia
[37] According to Jui Han Cephalotaxus hainanesis and
Camptotheca accuminata showed antineoplastic activity
[38]. Clinical studies of harringtonine from Cephalotaxus
harringtonia in China showed that it had a certain effect on
various types of acute leukemia by intravenous administra-
tion. Furthermore, patients who had become resistant to
treatment with other chemotherapeutic drugs had been
reported to respond to treatment with the cephalotaxine
esters [39]. Based on literature review, we concluded that
there is no sufficient information available on any signifi-
cant activity of Cephalotaxus sinensis. All above mentioned
results are novel and reported first time.
Conclusion
In conclusion, the present study demonstrated that the
treatment of diabetic rats with Cephalotaxus sinensis could
ameliorate the impaired renal function and inhibit liver
damage associated with STZ-induced diabetes. Based on
experimentally demonstrated properties, it is a valuable
candidate for developing new phytotherapeutics agent. The
isolation and testing of constituents likely to be responsible
for the hepato-renal protective activities of C. sinensis is
under progress in our lab.
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